Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Neurology/Psychiatric

Novel GPR139 agonist evaluated in schizophrenia mouse model

Nov. 28, 2023

GPR139 is an orphan G protein-coupled receptor expressed in neurons of the mediobasal hypothalamus that has been proposed as a target for disorders such as Parkinson’s disease, alcohol addiction or schizophrenia, among others.

Stroke illustration: brain, artery, neurons

Neurology/Psychiatric

Discovery of neuroprotective agent for ischemic stroke reported

Nov. 28, 2023

In stroke, one of the events underlying neuronal injury is the interaction of neuronal nitric oxide synthase (nNOS) with postsynaptic density protein 95 (PSD-95) leading to nitric oxide overproduction.

Neurology/Psychiatric

Discovery of AChE inhibitor with promising activity in models of Alzheimer’s disease

Nov. 27, 2023

Researchers from the National Research Centre of Egypt and Cairo University have reported the discovery of novel acetylcholinesterase (AChE) inhibitors as candidates for the management of Alzheimer’s disease.

Neurology/Psychiatric

Researchers identify new highly selective dopamine D2 receptor antagonist

Nov. 27, 2023

Research at the National Institute of Neurological Disorders and Stroke has led to the identification of a novel highly selective D2R antagonist.

Parkinson's disease illustration showing neurons containing alpha-synuclein

Neurology/Psychiatric

USP30 loss or inhibition enhances mitophagy in Parkinson’s disease mouse model

Nov. 27, 2023

Scientists from the University of Cambridge, Harvard Medical School and collaborators investigated the potential of ubiquitin carboxyl-terminal hydrolase 30 (USP30) inhibition as a therapeutic strategy for restoring mitophagy to achieve neuroprotection in Parkinson’s disease.

Neurology/Psychiatric

Neumora’s M4 receptor positive allosteric modulator enters clinic for schizophrenia

Nov. 27, 2023

Neumora Therapeutics Inc. has announced IND clearance and initiation of a phase I study of NMRA-266 in healthy adults.

Neurology/Psychiatric

Unbiased screen uncovers γ-secretase targets far beyond amyloid

Nov. 27, 2023

By Anette Breindl

Using microglia and an unbiased screening method, investigators have identified almost 60 previously unknown targets for γ-secretase. Investigators from KU Leuven and colleagues published their results in Molecular Cell on Nov. 16, 2023.

Neurology/Psychiatric

Serpin Pharma describes new LRP-1 agonists

Nov. 23, 2023

Serpin Pharma LLC has identified serpin peptide derivatives acting as pro-low-density lipoprotein receptor-related protein 1 (LRP-1) agonists reported to be useful for the treatment of acute lung injury, eosinophilic esophagitis, viral infection, and acute and neuropathic pain, among others.

Neurology/Psychiatric

Siteone Therapeutics patents new Nav1.8 blockers for pain

Nov. 23, 2023

Siteone Therapeutics Inc. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Neurology/Psychiatric

MIRA-1a treatment results in cognitive enhancement in mice

Nov. 23, 2023

Mira Pharmaceuticals Inc. has reported findings on the cognitive enhancing effects of MIRA-1a, an unscheduled novel synthetic tetrahydrocannabinol (THC) analogue, in normal mice.

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...

BioWorld Science, Neurology/psychiatric RSS

BioWorld Science, Neurology/psychiatric
RSS